Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of Atopic Dermatitis (AD) for at least 3 months
Investigator's Global Assessment (IGA) score of 2 (mild), or 3 (moderate)
AD covering 5% and up to 40% of Body Surface Area (BSA)
A Peak Pruritus Numerical Rating Scale (PP-NRS) average score of ≥2
Diagnosis of Plaque Psoriasis (PsO) for at least 6 months
Physician Global Assessment (PGA) score of 2 (mild), 3 (moderate), or 4 (severe)
PsO covering 2% to 20% (inclusive) of BSA
You may not be if
Presence of skin comorbidities that would interfere with study assessment or response to treatment
Psychiatric condition including recent or active suicidal ideation or behavior
Current or recent history of severe, progressive, or uncontrolled disease
A history of systemic, chronic or acute skin infection requiring hospitalization, parenteral antimicrobial therapy, or is judged clinically significant.
Recent, significant trauma or major surgery
History of cancer or have undergone treatment for any type of cancer, with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ with no evidence of recurrence.
History of angioedema or anaphylaxis to topical products or known sensitivity to any of the components of the investigational products.
Use of any prohibited concomitant medication(s)
Previous administration with an investigational drug within 30 days or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer).
Participants with an estimated glomerular filtration rate (eGFR) of \<40 mL/min/1.73m2 calculated using the serum creatinine-based Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula for adults and serum creatinine \>1.5 x upper limit of normal (ULN) in adolescents (12-18 years old)
Participants with total bilirubin ≥2x ULN (≥3 x ULN for Gilbert's disease), aspartate aminotransferase (AST) ≥2.5 x ULN, ALT ≥2.5 x ULN.
Clinically relevant abnormal baseline standard 12-lead electrocardiogram (ECG) including, but not limited to QTC corrected using Fridericia's Formula (QTcF) interval \>450 msec and QRS \> 120 msec
A recent history of alcohol or substance abuse
Clareo Health | A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.
